Product NDC: | 63323-104 |
Proprietary Name: | Etoposide |
Non Proprietary Name: | ETOPOSIDE |
Active Ingredient(s): | 20 mg/mL & nbsp; ETOPOSIDE |
Administration Route(s): | INTRAVENOUS |
Dosage Form(s): | INJECTION, SOLUTION |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 63323-104 |
Labeler Name: | APP Pharmaceuticals, LLC |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | ANDA074983 |
Marketing Category: | ANDA |
Start Marketing Date: | 20010718 |
Package NDC: | 63323-104-05 |
Package Description: | 10 BOX in 1 CARTON (63323-104-05) > 1 VIAL, MULTI-DOSE in 1 BOX > 5 mL in 1 VIAL, MULTI-DOSE |
NDC Code | 63323-104-05 |
Proprietary Name | Etoposide |
Package Description | 10 BOX in 1 CARTON (63323-104-05) > 1 VIAL, MULTI-DOSE in 1 BOX > 5 mL in 1 VIAL, MULTI-DOSE |
Product NDC | 63323-104 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | ETOPOSIDE |
Dosage Form Name | INJECTION, SOLUTION |
Route Name | INTRAVENOUS |
Start Marketing Date | 20010718 |
Marketing Category Name | ANDA |
Labeler Name | APP Pharmaceuticals, LLC |
Substance Name | ETOPOSIDE |
Strength Number | 20 |
Strength Unit | mg/mL |
Pharmaceutical Classes | Topoisomerase Inhibitor [EPC],Topoisomerase Inhibitors [MoA] |